Compare RIVN & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RIVN | UTHR |
|---|---|---|
| Founded | 2009 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.1B | 23.9B |
| IPO Year | 2021 | 1999 |
| Metric | RIVN | UTHR |
|---|---|---|
| Price | $14.87 | $535.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 14 |
| Target Price | $17.89 | ★ $531.79 |
| AVG Volume (30 Days) | ★ 26.2M | 466.2K |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.54 | 13.07 |
| EPS | N/A | ★ 27.86 |
| Revenue | ★ $5,387,000,000.00 | $1,483,300,000.00 |
| Revenue This Year | $33.90 | $7.77 |
| Revenue Next Year | $63.73 | $11.11 |
| P/E Ratio | ★ N/A | $19.12 |
| Revenue Growth | ★ 8.39 | 2.38 |
| 52 Week Low | $10.36 | $266.98 |
| 52 Week High | $22.69 | $548.12 |
| Indicator | RIVN | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 44.19 | 62.29 |
| Support Level | $14.62 | $464.92 |
| Resistance Level | $16.17 | N/A |
| Average True Range (ATR) | 0.74 | 19.31 |
| MACD | 0.07 | 4.83 |
| Stochastic Oscillator | 11.77 | 88.41 |
Rivian is a battery electric vehicle automaker that sells its vehicles in the US and Canada. The company also develops electronic control units and related software for autos in a joint venture with Volkswagen. Rivian has multiple vehicles in its fleet, which include a luxury truck and full-size SUV and a delivery van. The company also plans to begin selling a midsize SUV in 2026. Total deliveries were nearly 52,000 in 2024. Rivian is also developing autonomous driving software to be used in its vehicles.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.